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was 90% (95%CI: 82-98) with a median chimerism of 100% (range
72-100) by day 100. The cumulative incidences of grade II-IV and
grade III-IV acute GVHD were 61% (95%CI: 14-78) and 27%
(95%CI: 14-40) at day 100, and chronic GVHD was 36% (95%CI:
20-52) at 1 year. TRM was 18% (95%CI: 8-28) at day 180, and
relapse/progressive disease was 31% (95%CI: 17-45) at 1 year.
Regression of relapsed or persistent disease has been seen in pa-
tients with myelodysplasia and intermediate and low grade lym-
phoid malignancies (n  8). The probability of overall and pro-
gression-free survival was 57% (95%CI: 40-73) and 48% (95%CI:
32-63) at 1 year. Notably, day 180 transplant related mortality
(TRM) in patients aged 45 years was 11% (95%CI: 1-21), and in
patients with extensive prior therapy was 25% (95%CI: 6-44).
However, patients with serious co-morbidities pre-transplant had a
high TRM of 45% (95%CI: 20-70) at day 180 (p  0.01). These
data suggest that this regimen is both non-myeloablative and as-
sociated with a high incidence of donor engraftment with low
toxicity. Further, this approach appears to extend access to trans-
plant to many adults who would otherwise be ineligible based on
lack of donor and/or inability to tolerate high-dose conditioning.
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CLINICAL RESULTS IN UMBILICAL CORD BLOOD RECIPIENTS WITH
HEMATOLOGICAL MALIGNANCIES USING MYELOABLATIVE REGIMENS
Takahashi, S. University of Tokyo, Japan.
Unrelated cord blood transplantation (CBT) has now become
more common, but as yet there have been only a few reports on its
outcome in adults. We studied the clinical outcomes of 68 adult
patients with hematological malignancies who received unrelated
CBT and compared with bone marrow transplantation (BMT,
n45) from unrelated donors. All recipients received transplanta-
tions after myeloablative regimens including 12 Gy of TBI be-
tween 1996 and 2003. We analyzed the hematopoietic recovery,
rates of GVHD, risks of TRM and relapse, and DFS using Cox
proportional-hazard regression models. The time from donor-
search to transplantation was signiﬁcantly shorter among CBT
recipients (median 3 months) than BMT recipients (median 11
months). The 6 possible matches between the recipient and the
donor were scored serologically for HLA-A and B and genetically
for DRB1 alleles and the results showed 39 (87 %) matched grafts
in BMT and no complete matches in CBT. Although the number
of leukocytes for CBT was 1 log lower than in BMT, 64 out of 68
(94 percent) cord blood grafts contained more than 2.0  107 cells
per kilogram. Multivariate analysis demonstrated slow neutrophil
and platelet recoveries in CBT compared with BMT. Despite the
higher HLA mismatching rate and less use of immunosuppressive
drugs such as steroids even in recipients affected with acute GVHD
higher than grade II, probability of grades III and IV acute GVHD
was signiﬁcantly lower than among BMT recipients in multivariate
analysis. There were no GVHD-related deaths among CBT recip-
ients, compared with 10 deaths out of 24 among BMT recipi-
ents. On the other hand, There was no signiﬁcant difference
between CBT and BMT recipients in chronic GVHD inci-
dence. Unrelated CBT showed better TRM, relapse and DFS
results compared with BMT. These data strongly suggest that
CBT could be safely and effectively used for adult patients with
hematological malignancies.
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COMPARISON OF UNRELATED CORD BLOOD AND BONE MARROW
TRANSPLANTS IN ADULTS WITH ACUTE LEUKEMIA
Gluckman, E. Eurocord Hospital Saint Louis, Paris, France.
Background. Unrelated cord blood is an alternative to bone
marrow cell transplantation in patients with hematopoietic dis-
eases, mainly in children. The objective of this study was to com-
pare both sources of stem cells to treat adults with acute leukemia
(AL). Patients and Methods. We compared 98 adults with AL
given an HLA-incompatible unrelated cord blood transplants
(UCBT) with 584 HLA-matched unrelated bone marrow trans-
plants (UBMT) performed between 1998 and 2002 and reported to
the Eurocord and European Blood and Marrow Transplant regis-
try. Outcomes were compared using multivariate analysis to adjust
for confounding clinical factors. Results. Recipients of UCBT
were younger (median 24.5 versus 32 years, p0.001), weighed less
(median 58 versus 68 kg, p0.001), and had more advanced disease
at transplant (52% versus 33%, p0.001). All UBMT were HLA-
matched whereas most of UCBT were HLA-incompatible
(p0.0001). The median number of nucleated cord blood cells
infused was 0.23  108/kg compared with 2.9  108/kg nucleated
bone marrow cells (p0.001). Multivariate analysis demon-
strated lower risks of grade II-IV acute graft versus-host disease
(p0.001) after UCBT, however neutrophil recovery was sig-
niﬁcantly delayed (p0.001). Transplantation-related mortality,
relapse, chronic GvHD, and leukemia-free survival were com-
parable between UCBT and UBMT recipients. Conclusion.
These results suggest that UCBT is an alternative treatment for
adults with AL lacking an HLA-matched sibling bone marrow
donor.
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Sanz, G.F., Moscardó, F., Jiménez, C., Lorenzo, I., Planelles, D.,
Larrea, L., Cervera, J., Benlloch, L., Barragán, E., Senent, L., Cantero,
S., Montesinos, P., Remigia, M.J., Sanz, M.A. Hospital Universitario
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Spain.
Despite the promising results with imatinib, allogeneic stem cell
transplantation remains the only proven curative approach for
patients with chronic myeloid leukemia (CML). This study reports
the results of unrelated-donor cord blood transplantation (UD-
CBT) in a series of 20 patients with CML treated in a single
institution. Fourteen were in chronic phase (CP; 8 in CP1 and 6 in
CP2), 2 in accelerated phase and 4 in blast crisis. Median age was
32 years (range, 16-46). Conditioning consisted of thiotepa, busul-
fan, cyclophosphamide and antithymocyte globulin, and GVHD
prophylaxis of cyclosporine and prednisone. HLA match was 5/6 in
7 cases and 4/6 in 13. The median number of nucleated and
CD34 cells infused was 1.8  107/kg (range, 1.2-4.9) and 0.8 
105/kg (range, 0.3-2.2), respectively. Median time to PMN above
0.5  109/L and to platelets above 20  109/L was 22 days (range,
10-52) and 69 days (range, 43-188), and the cumulative incidence
of myeloid and platelet engraftment was 85% and 45%, respec-
tively. Time to myeloid engraftment showed a direct relationship
with the number of CFU-GM (P .009) and CD34 cells (P .02)
infused. Platelet engraftment was faster in patients receiving a
higher number of CFU-GM (P .05), in those transplanted in CP
(P  .04) and in those not developing acute GVHD above grade I
(P  .001). Eight patients developed acute GVHD above grade II,
and 7 of 11 patients at risk had extensive chronic GVHD. With a
median follow-up of 49 months (range, 28-82), the probability of
disease-free survival (DFS) at 3 years was 40% and was related to
age (P  .01) and phase of the disease at transplant (P  .04). The
probability of DFS at 3 years was 60% for patients younger than 31
years and 57% for those transplanted in CP. Six of 8 patients aged
30 years or younger and transplanted in CP remain alive and
disease-free. These data suggest that UD-CBT is an acceptable
alternative for younger patients with CML in CP requiring trans-
plantation and lacking a HLA-matched family or unrelated bone
marrow donor.
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MARROW TRANSPLANTS FOR ADULTS WITH LEUKEMIA A Collabora-
tive Study: The New York Blood Center National Cord Blood Pro-
gram And The International Bone Marrow Transplant Registry
Laughlin, M.J. Case Western Reserve University, Cleveland, Ohio.
Though little is known regarding the safety and efﬁcacy of
umbilical cord blood (UCB) transplantation in adults, these are
increasingly used in older subjects. We compared the results of
169, 1-antigen mismatched UCB, 83, 1-antigen mismatched and
367, matched bone marrow (BM) transplants in patients age 16-60
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